Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Summary of Financial Information for the Company's Segments

Summarized financial information for the Company’s segments is shown in the following tables:

(in thousands)	Three Months Ended March 31,
	2025		2024
Revenue
Patient services	$	53,068	$	52,453
Dispensary	49,293		39,679
Clinical trials & other	2,045		2,534
Consolidated revenue	$	104,406	$	94,666
Direct costs
Intravenous (IV) drug costs	$	31,413	$	32,724
Clinician salaries and benefits	14,074		15,461
Medical supplies and other	1,593		1,312
Total patient services (A)	$	47,080	$	49,497
Dispensary (B)	39,863		32,809
Clinical trials & other (C)	214		391
Total segment direct costs	$	87,157	$	82,697
Depreciation expense
Patient services	$	755	$	515
Dispensary	32		31
Clinical trials & other	2		—
Total segment depreciation expense	$	789	$	546
Amortization of intangible assets
Patient services	$	718	$	718
Clinical trials & other	55		55
Total segment amortization	$	773	$	773
Operating income
Patient services	$	4,515	$	1,723
Dispensary	9,398		6,839
Clinical trials & other	1,774		2,088

(in thousands)	Three Months Ended March 31,
	2025		2024
Total segment operating income	$	15,687	$	10,650
Other items not allocated to segments:
Selling, general and administrative expense	$	25,376	$	28,452
Non-segment depreciation and amortization	222		170
Total consolidated operating loss	$	(9,911)	$	(17,972)
Interest expense, net	5,570		1,985
Change in fair value of derivative warrant liabilities	43		—
Change in fair value of conversion option derivative liabilities	3,309		—
Other, net	752		(68)
Consolidated loss before provision for income taxes	$	(19,585)	$	(19,889)

(in thousands)	March 31, 2025		December 31, 2024
Assets
Capitated accounts receivable	$	3,883	$	3,695
FFS accounts receivable	28,593		26,532
IV drug inventory	6,518		6,556
Other assets	26,760		31,667
Patient services	65,754		68,450
Oral drug accounts receivable	7,623		6,371
Oral drug inventory	5,790		3,483
Other assets	3,328		4,574
Dispensary	16,741		14,428
Clinical trials & other	8,001		7,974
Non-segment assets	73,506		81,865
Total assets	$	164,002	$	172,717